Article

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX models

2025-11-11

Abstract excerpt

<title>Abstract</title> <p>MDM2 is an E3 ubiquitin ligase that promotes p53 tumor suppressor degradation and has emerged as a therapeutic target in the treatment of wild-type (wt) TP53 tumors. In acute myeloid leukemia (AML), TP53 mutations are infrequent (15-20%) but wt-p53 is often inactivated through overexpression of MDM2. Thus, MDM2 inhibitors are currently in clinical trials for AML. However, p53 stabilizat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9c9cdee0-b837-5c8a-8f16-0a6942c3115f
DOI: 10.21203/rs.3.rs-7982024/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Activity of PROTAC MDM2 Degrader in Primary Leukemia Cells and PDX modelsDOI 10.21203/rs.3.rs-7982024/v1Read

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor RegressionSemantic proximity Read

PROTAC degraders with ligands recruiting MDM2 E3 ubiquitin ligase: an updated perspectiveSemantic proximity Read

Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.Semantic proximity Read

MDM2 Antagonists and p53-Targeting Therapies in Cancer: Clinical Applications, Adverse Effects, and Resistance MechanismsSemantic proximity Read

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read

Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.Semantic proximity Read

Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes tyrosine kinase inhibitor resistance of acute myeloid leukemia cellsSemantic proximity Read

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.Semantic proximity Read

A therapeutic patent overview of MDM2/X-targeted therapies (2014–2018)Semantic proximity Read

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.Semantic proximity Read

Rapid proteasomal degradation of mutant feline McDonough sarcoma-like tyrosine kinase-3 overcomes inhibitor resistance mechanisms of acute myeloid leukemia cellsSemantic proximity Read

High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemiaSemantic proximity Read